OncoMatch/Clinical Trials/NCT03400826
Effects of Simvastatin on Uterine Leiomyoma Size
Is NCT03400826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Simvastatin 40mg for fibroid uterus.
Treatment: Simvastatin 40mg — The study aims to study the effect of simvastatin on the size of uterine fibroids.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
Hemoglobin ≤ 6 g/dL [excluded]
Liver function
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit) [excluded]
Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit); Hemoglobin ≤ 6 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Hospital · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03400826 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 55 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify